Juventas Cell Therapy’s CNCT19 Receives FDA IND Approval for r/r B-ALL Treatment
China-based Juventas Cell Therapy Ltd’s chimeric antigen receptor (CAR) T-cell therapy, CNCT19 (Inaticabtagene Autoleucel), has...
Clinical trial approval / initiation
Bio-Thera Solutions Initiates First Patient Dosing in Phase I Study of BAT8007
China-based Bio-Thera Solutions, Ltd. (SHA: 688177) has announced the first patient dosing in a multi-center,...
Antengene to Begin Phase I Clinical Study of ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Ltd (HKG: 6996) is poised to commence a Phase I clinical study...
Guangdong Zhongsheng’s RAY1225 Receives NMPA Approval for Clinical Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received approval...
Boston Scientific Launches REPLACE Study for FARAPULSE PFA System in China
US-based medical technology major Boston Scientific Corporation (NYSE: BSX) has announced the initiation of the...
Haihe Pharmaceutical Initiates Global Phase I Clinical Study for BET-BD2 Inhibitor HH3806
Shanghai Haihe Pharmaceutical Co., Ltd has announced the first patient dosing of a global multi-center...
CanSino Biologics Initiates Phase Ib Study for Innovative Protein-Based Pneumococcal Vaccine
China-based vaccines specialist CanSino Biologics Inc. has announced the initiation and first subject enrollment of...
Simcere’s SIM0237 Begins Clinical Study for PD-L1 and IL-15 Targeting Bispecific Antibody
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
Simcere Pharmaceutical Initiates Clinical Study for Bispecific Antibody SIM0237 in Advanced Tumors
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the first patient in (FPI) a clinical...
Bio-Thera Solutions Initiates Phase I Study for Trop2-Targeting ADC BAT8008
China-based Bio-Thera Solutions, Ltd (SHA: 688177) has announced the first patient dosing in a multi-center,...
InnoCare Pharma Initiates Clinical Study for BCL2 Inhibitor ICP-248 in China
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced the first subject dosing in a...
JW Therapeutics Launches Carteyva Clinical Study for High-Risk Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
JW Therapeutics Initiates Clinical Study for Carteyva in First-Line High-Risk Large B-Cell Lymphoma
China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical...
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
AffaMed Technologies Completes First Patient Implantation for MINI WELL IOL
AffaMed Technologies, a joint venture between AffaMed Therapeutics and SIFI S.p.A., has announced the completion...
CSPC Pharmaceutical Initiates Phase III Study for Mitoxantrone Liposome in Nasopharyngeal Carcinoma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced the first patient dosing in a...
OcuMension Therapeutics Initiates Phase II Study for Dry Eye Treatment OT-202
Chinese ophthalmology specialist OcuMension Therapeutics (HKG: 1477) has announced the initiation of a randomized, double-blind,...